Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix

Dow Jones

03/02

By Colin Kellaher

Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen.

Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers.

San Diego-based Gyre said it expects to complete the acquisition early in the second quarter.

Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement.

Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 02, 2026 10:23 ET (15:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2616020356"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616020356\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616020356?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616020356","market":"nz","top_or_hot":-1,"title":"Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n</p>\n<p>\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n</p>\n<p>\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n</p>\n<p>\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n</p>\n<p>\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 10:23 ET (15:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-02 23:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n</p>\n<p>\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n</p>\n<p>\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n</p>\n<p>\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n</p>\n<p>\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 10:23 ET (15:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GYRE","symbol_name":"Gyre Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616020356","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616020356","pubTimestamp":1772464980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Gyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen.Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers.San Diego-based Gyre said it expects to complete the acquisition early in the second quarter.Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement.Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GYRE":"Gyre Therapeutics","PULM":"Pulmatrix, Inc.","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Gyre Therapeutics收购Cullgen，结束与Pulmatrix的合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PULM":1.5,"GYRE":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\nGyre Therapeutics has agreed to buy privately held, clinical-stage biopharmaceutical company Cullgen in an all-stock transaction valued at about $300 million, upending plans by Pulmatrix to merge with Cullgen. \n\n\n  Gyre on Monday said the acquisition of Cullgen will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a pipeline of degraders, targeting inflammatory diseases and cancers. \n\n\n  San Diego-based Gyre said it expects to complete the acquisition early in the second quarter. \n\n\n  Pulmatrix, a Framingham, Mass., biopharmaceutical company, in late 2024 agreed to merge with China-based Cullgen, but the deal encountered regulatory delays in China, and Pulmatrix on Monday said Cullgen had terminated the agreement. \n\n\n  Pulmatrix said it has been working to identify an alternative reverse merger opportunity, adding that it is encouraged by the interest it has received and a recent increase in deal activity within its industry. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 10:23 ET (15:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}